Swiss generic and biosimilar medicines company Sandoz has reached agreement with US biotech major Amgen to resolve all patent disputes between the two companies 30 April 2024
Swedish Orphan Biovitrum, a rare disease company also known as Sobi, is set to raise around 10 billion Swedish kroner ($920 million) in debt. 26 April 2024
A first-in-class treatment for paroxysmal nocturnal haemoglobinuria (PNH), Voydeya (danicopan), has been granted marketing authorization in Europe. 23 April 2024
Menarini Stemline has welcomed the publication of final draft guidance from the National Institute for Health and Care Excellence (NICE) recommending the use of 22 April 2024
Roche’s CD20xCD3 T-cell engaging bispecific antibody Columvi (glofitamab) has met the primary endpoint of overall survival in relapsed or refractory diffuse la 15 April 2024
Data from the RESMAIN study of Kinselby (resminostat) have been presented at the 5th World Congress of Cutaneous Lymphomas (5WCCL), at the City of Hope, Pasaden 11 April 2024
There has been an uptick in licensing agreements for drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology ove 10 April 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.